The use of estramustine phosphate in the modern management of advanced prostate cancer

BJU International

Volumn 108, Issue 11, 2011, Pages 1782-1786

  Ravery, Vincent ^a   Fizazi, Karim ^b   Oudard, Stephane ^c   Drouet, Ludovic ^d   Eymard, Jean Christophe ^e   Culine, Stephane ^f   Gravis, Gwenaelle ^g   Hennequin, Christophe ^h   Zerbib, Marc ⁱ  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ Institut Cochin   (France)

Author keywords

chemotherapy; docetaxel; estramustine; Hormone resistant prostate cancer; low molecular weight heparin

Indexed keywords

DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; ESTRAMUSTINE PHOSPHATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MITOXANTRONE; NAVELBINE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; WARFARIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HORMONE RESISTANT PROSTATE CANCER; HUMAN; META ANALYSIS (TOPIC); NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; MALE; NAUSEA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TAXOIDS; THROMBOEMBOLISM; TREATMENT OUTCOME; VOMITING;

EID: 81255161754     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10201.x     Document Type: Article

References (21)

1. Tannock IF, Osoba D, Stockler MR, et al,. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64 (Pubitemid 26185452)
2. Kantoff PW, Halabi S, Conaway M, et al,. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-13 (Pubitemid 29368252)
3. Petrylak DP, Tangen CM, Hussain MH, et al,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20 (Pubitemid 39315318)
4. Tannock IF, de Wit R, Berry WR, et al,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 (Pubitemid 39315317)
5. Perry CM, McTavish D,. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1995; 7: 49-74
6. Oudard S, Banu E, Beuzeboc P, et al,. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005; 23: 3343-51
7. Eymard JC, Priou F, Zannetti A, et al,. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 2007; 18: 1064-70 (Pubitemid 47050499)
8. Caffo O, Sava T, Comploj E, et al,. Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int 2008; 102: 1080-5
9. Machiels JP, Mazzeo F, Clausse M, et al,. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008; 26: 5261-8
10. Caffo O, Sava T, Comploj E, et al,. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol Oncol 2010; 28: 152-6
11. Culine S, Droz JP,. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? Ann Oncol 2000; 11: 1523-30 (Pubitemid 32104749)
12. Pectasides D, Pectasides E, Papaxoinis G, et al,. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience. Anticancer Res 2009; 29: 769-75
13. Samelis GF, Kalofonos H, Adamou A, et al,. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. Urology 2005; 66: 382-5 (Pubitemid 41138102)
14. Oudard S, Eymard JC, Fizazi K,. Combining docetaxel with estramustine: back to the future. J Clin Oncol 2009; 27: 1148-9
15. Fizazi K, Le Maitre A, Hudes G, et al,. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007; 8: 994-1000 (Pubitemid 47629887)
16. Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ,. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis. Cancer 2004; 101: 2755-9 (Pubitemid 39603183)
17. Zwicker JI,. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 2008; 34: 195-8
18. Ay C, Simanek R, Vormittag R, et al,. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112: 2703-8
19. Kakkar AK, Levine MN, Kadziola Z, et al,. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-8 (Pubitemid 41095187)
20. Palumbo A, Rajkumar SV, Dimopoulos MA, et al,. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-23 (Pubitemid 351255436)
21. Akl EA, Barba M, Rohilla S, et al,. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008; CD006650